首页> 外文期刊>Annals of Surgery >Efficacy of a Single Preoperative Dexamethasone Dose to Prevent Nausea and Vomiting After Thyroidectomy (the tPONV Study) A Randomized, Double-blind, Placebo-controlled Clinical Trial
【24h】

Efficacy of a Single Preoperative Dexamethasone Dose to Prevent Nausea and Vomiting After Thyroidectomy (the tPONV Study) A Randomized, Double-blind, Placebo-controlled Clinical Trial

机译:术前单次地塞米松剂量预防甲状腺切除术后恶心和呕吐的功效(tPONV研究)一项随机,双盲,安慰剂对照的临床试验

获取原文
获取原文并翻译 | 示例
           

摘要

Objective: Does dexamethasone given before thyroidectomy reduce postoperative nausea and vomiting (PONV) in a randomized controlled trial? Background: PONV is an unsettling problem that commonly occurs in patients after thyroidectomy. Various preventive measures have been studied; however, many of these studies have been criticized for their biases (eg, use of opioids, sex selection) or were even retracted. Methods: This single-institution, randomized, double-blind, placebo-controlled, superiority study was performed between January 1, 2011, and May 30, 2013. Patients undergoing thyroidectomy for benign disease were allocated by a block randomized list to receive a preoperative single dose of dexamethasone (8mg) or placebo. Patients and staff were blinded to the treatment assignment. The primary endpoint was the incidence of PONV assessed at 4,8,16,24,32, and 48 hours after surgery. To observe an incidence reduction of 50%, a total of 152 patients were required for the study. Results: The total incidence of PONV was reported in 65 of 152 patients (43%; 95% confidence interval [CI], 35-51). In the intention-to-treat analysis, PONV occurred in 22 of 76 patients (29%; 95% CI, 20-40) in the treatment arm and in 43 of 76 patients (57%; 95% CI, 45-67) in the control arm (P = 0.001; odds ratio = 0.31; 95% CI, 0.16-0.61; absolute risk reduction = 28%; 95% CI, 12-42). The number needed to treat was 4. No severe dexamethasone-related adverse events were observed during the study. Conclusions: A single dose of preoperative dexamethasone administration is an effective, safe, and economical measure to reduce PONV incidence after thyroidectomy.
机译:目的:在一项随机对照试验中,甲状腺切除术前给予地塞米松是否可以减少术后恶心和呕吐(PONV)?背景:PONV是一个令人不安的问题,通常发生在甲状腺切除术后的患者中。已经研究了各种预防措施;然而,许多这类研究因其偏见(例如使用阿片类药物,性别选择)而受到批评,甚至被撤回。方法:这项于2011年1月1日至2013年5月30日进行的单机构,随机,双盲,安慰剂对照的优势研究。将甲状腺良性疾病摘除术的患者按随机分组分配,接受术前治疗。单次地塞米松(8mg)或安慰剂。患者和医务人员对治疗任务不了解。主要终点是术后4、8、16、24、32和48小时评估的PONV发生率。为了观察发病率降低50%,该研究总共需要152名患者。结果:152例患者中有65例报告了PONV的总发生率(43%; 95%置信区间[CI],35-51)。在意向治疗分析中,PONV发生在治疗组的76例患者中的22例(29%; 95%CI,20-40)和76例患者中的43例(57%; 95%CI,45-67)在对照组中(P = 0.001;优势比= 0.31; 95%CI,0.16-0.61;绝对风险降低= 28%; 95%CI,12-42)。需要治疗的数量为4。在研究过程中未观察到严重的地塞米松相关不良事件。结论:术前单剂量地塞米松给药是减少甲状腺切除术后PONV发生率的有效,安全和经济的措施。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号